Mode
Text Size
Log in / Sign up

Sublobar resection associated with improved overall survival compared to SBRT in early-stage non-small cell lung cancerSublobar Resection Shows Better Survival Than Radiation for Lung Cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that sublobar resection is associated with improved overall survival compared to SBRT in early-stage NSCLC.

This systematic review and meta-analysis evaluates the comparative outcomes of sublobar resection (SLR), stereotactic body radiation therapy (SBRT), and image-guided thermal ablation (IGTA) in patients with pathologically confirmed early-stage non-small cell lung cancer (NSCLC) who are unable to tolerate a lobectomy. The study synthesizes data from propensity score-matched studies to compare these treatment modalities.

The meta-analysis found that SLR was associated with improved overall survival (OS) compared with SBRT (1.51; 95% CI: 1.18-1.93). In terms of cancer-specific survival (CSS), no significant difference was observed between SLR and SBRT (1.08; 95% CI: 0.48-2.45). Pooled data for 3-year OS showed rates of 80% for SLR, 64% for SBRT, and 64% for IGTA. For 3-year CSS, the pooled rates were 88% for SLR, 84% for SBRT, and 76% for IGTA.

While SLR showed a statistically significant association with better overall survival, the authors note that SBRT and IGTA represent acceptable alternatives for patients who are not candidates for traditional surgery. Treatment selection should be individualized based on patient factors. No specific limitations were reported.

How this fits prior evidence

This meta-analysis addresses a gap in comparing surgical and non-surgical options for early-stage NSCLC patients unable to undergo lobectomy. While previous coverage has focused on systemic therapies like Osimertinib, ALK inhibitors, and combinations such as Sacituzumab Tirumotecan with Pembrolizumab, this study provides evidence regarding local treatment modalities (SLR vs. SBRT/IGTA). It confirms that while SLR is associated with improved overall survival compared to SBRT, both SBRT and IGTA are acceptable alternatives for patients who cannot tolerate surgery.

This analysis looked at patients with early-stage non-small cell lung cancer (NSCLC) who were not able to undergo a standard lobectomy. The study compared three different treatments: sublobar resection (SLR), stereotactic body radiation therapy (SBRT), and image-guided thermal ablation (IGTA).

The findings showed that patients who received sublobar resection had a higher overall survival rate than those who received SBRT. Specifically, the 3-year survival rate for sublobar resection was 80 percent, while it was 64 percent for both SBRT and IGTA. While there was no significant difference in cancer-specific survival between surgery and radiation, the data suggests a link between smaller surgical procedures and better overall outcomes.

Because these treatments are often used when traditional surgery is not an option, they are considered acceptable alternatives. However, because this study shows an association rather than a direct cause, treatment choices should be based on individual patient needs. Talk to your doctor to determine which approach fits your specific health situation.

What this means for you:
Sublobar resection showed higher overall survival rates than radiation for certain early-stage lung cancer patients.

Common questions

How does sublobar resection compare to radiation?

The study found that sublobar resection was associated with improved overall survival compared to stereotactic body radiation therapy (SBRT). Specifically, the 3-year survival rate for sublobar resection was 80 percent, while it was 64 percent for SBRT.

Is there a difference in cancer-specific survival?

The study found no significant difference in cancer-specific survival between sublobar resection and SBRT. While the 3-year cancer-specific survival rates were 88 percent for surgery and 84 percent for radiation, the gap was not statistically significant.

Study Details

Study typeMeta analysis
EvidenceLevel 1
Follow-up36.0 mo
PublishedJul 2026
View Original Abstract ↓
INTRODUCTION: For patients with early-stage non-small cell lung cancer (NSCLC) who are unable to tolerate lobectomy, alternative locoregional treatments, including sublobar resection (SLR), stereotactic body radiation therapy (SBRT), or image-guided thermal ablation (IGTA) are available, yet their relative risks and benefits remain uncertain. This systematic review and meta-analysis aims to synthesize existing evidence and compare the survival outcomes of these modalities in early-stage NSCLC. METHODS: A systematic search was conducted through MEDLINE (PubMed), Embase, and CENTRAL on April 20, 2026. Comparative analyses were restricted to propensity score-matched (PSM) studies reporting hazard ratios (HRs) for overall survival (OS) and cancer-specific survival (CSS) in pathologically confirmed early-stage NSCLC. Single-arm pooled survival analyses were performed using reconstructed individual patient data to estimate time-to-event outcomes. Risk of bias was assessed using ROBINS-I for comparative analysis and the JBI checklist for single-arm analyses. RESULTS: Seven PSM studies comparing SBRT and SLR were included in the comparative analysis. SLR was associated with improved OS compared with SBRT (HR 1.51; 95% CI: 1.18-1.93), while CSS did not differ significantly (HR 1.08; 95% CI: 0.48-2.45). Sixteen studies were included in the single-arm analyses. Pooled 3-year OS estimates were 80% (95% CI: 75-86%) for SLR, 64% (95% CI: 56-73%) for SBRT, and 64% (95% CI: 48-86%) for IGTA. Corresponding pooled 3-year CSS estimates were 88% (95% CI: 84-92%), 84% (95% CI: 82-87%), and 76% (95% CI: 50-100%), respectively. CONCLUSIONS: SLR was associated with improved OS, although CSS did not differ significantly between the modalities. SBRT and IGTA represent acceptable alternatives in patients unsuitable for surgery. Treatment selection should be individualized through multidisciplinary assessment.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.